Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Lipocine Inc (LPCN) USD0.0001

Sell:$0.94 Buy:$1.01 Change: $0.0114 (1.23%)
Market closed |  Prices as at close on 29 May 2020 | Switch to live prices |
Change: $0.0114 (1.23%)
Market closed |  Prices as at close on 29 May 2020 | Switch to live prices |
Change: $0.0114 (1.23%)
Market closed |  Prices as at close on 29 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products. The Company's primary development programs are based on oral delivery solutions for bioavailable drugs. The Company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Its additional pipeline includes, an oral androgen therapy for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, LPCN 1144; a once daily oral testosterone replacement therapy, TLANDO XR (LPCN 1111); an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the prevention of preterm birth, LPCN 1107.

Contact details

675 S Arapeen Dr Ste 202
United States
+1 (801) 9947383

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$46.44 million
Shares in issue:
47.88 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Mahesh Patel
    Chairman of the Board, President, Chief Executive Officer
  • Morgan Brown
    Chief Financial Officer, Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.